← Back to Search

Treatment for Glioblastoma

N/A
Recruiting
Led By Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Summary

The purpose of this study is to better define longitudinal genomic alterations in patients with glioblastoma (GBM), and to determine if plasma circulating tumor DNA (ctDNA) or cell free DNA (cfDNA) is associated with disease recurrence, survival, tumor characteristics, and/or peripheral immunosuppression.

Eligible Conditions
  • Glioblastoma
  • Malignant Glioma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Median cf/ctDNA concentration at pre- and post-radiation, as well as median change in ct/ctDNA concentration
Median levels of cfDNA collected longitudinally after completion of radiation
Other study objectives
Characterize the fragmentomic landscape of GBM
Hazard ratio for the relationship between chromosomal instability and OS or PFS
Median and range for measures of tumor immune infiltration
+2 more

Find a Location

Who is running the clinical trial?

Personalis, Inc.UNKNOWN
Duke UniversityLead Sponsor
2,424 Previous Clinical Trials
3,065,984 Total Patients Enrolled
39 Trials studying Glioblastoma
1,554 Patients Enrolled for Glioblastoma
Personalis Inc.Industry Sponsor
1 Previous Clinical Trials
422 Total Patients Enrolled
~67 spots leftby Jan 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top